

## PRODUCT INFORMATION

<b>Clone ID</b>	1G1
<b>Target</b>	SN38
<b>Synonyms</b>	N.A.
<b>Host Species</b>	Rabbit
<b>Description</b>	Anti-SN38 antibody(1G1); Rabbit mAb
<b>Delivery</b>	In Stock
<b>Uniprot ID</b>	N.A.
<b>IgG type</b>	Rabbit IgG
<b>Clonality</b>	Monoclonal
<b>Reactivity</b>	N.A.
<b>Applications</b>	ELISA
<b>Recommended Dilutions</b>	ELISA 1:5000-10000
<b>Purification</b>	Purified from cell culture supernatant by affinity chromatography
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.
<b>Background</b>	SN38, a potent chemotherapeutic derived from irinotecan, plays a pivotal role in colorectal cancer treatment. As the active form of irinotecan, SN38 operates as an effective DNA topoisomerase I inhibitor, inducing cell death in cancer cells. Notably, SN38's potential is harnessed in Antibody-Drug Conjugates (ADCs), where it is delivered to tumor sites through innovative methods like liposomes and nanoparticles. This targeted approach enhances SN38's efficacy, emphasizing its crucial role in ADC-based strategies for precise and potent colorectal cancer therapy.
<b>Usage</b>	Research use only
<b>Conjugate</b>	Unconjugated
<b>DIMA Disclaimer</b>	All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.



**ELISA assay to evaluate Anti-SN38 Antibody**  
0.2 $\mu$ g Human IgG-SN38 per well




Figure1. Elisa plates were pre-coated with IgG-SN38 (0.2 $\mu$ g/per well). Serial diluted anti-SN38 monoclonal antibody (DME101020) solutions were added, washed, and incubated with secondary antibody before Elisa reading. From above data, the EC50 for anti-SN38 monoclonal antibody binding with IgG-SN38 is 11.39ng/ml.

